GlassScriptPhysician profile
Jill L Raymer
NPI 1053780767
$3,686.67
in general payments reported to CMS, 2019-2025
19 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $898 · 2023: $686 · 2024: $593 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.47 |
| Education | $101.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.38 | 2021-2025 | |
| Novo Nordisk INC | $448.52 | 2022-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $233.36 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $231.36 | 2024-2025 | Evenity, Otezla, Repatha |
| Gilead Sciences, INC. | $200.30 | 2023-2025 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $193.46 | 2022 | |
| Astellas Pharma US INC | $169.99 | 2022-2023 | |
| Exact Sciences Corporation | $154.88 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $77.39 | 2021-2025 | Mounjaro, Zepbound |
| Indivior INC. | $75.57 | 2022-2025 | Sublocade |
| Axsome Therapeutics, INC. | $42.91 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $29.40 | 2023 | Abilify Maintena, Rexulti |
| Shield Therapeutics INC | $28.95 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.49 | 2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2023 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $16.24 | 2025 | Arikayce |
| Vanda Pharmaceuticals INC. | $15.48 | 2025 | Fanapt |
| Dexcom, INC. | $15.43 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Raymer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.